Skip to main content Skip to navigation

Professor Christopher Poole

Job Title
Professor of Oncology
Department
WMS - Cancer Research
Phone
02476967497
  • Conefrey, C., Donovan, J. L., Stein, R. C., Paramasivan, S., Marshall, Andrea, Bartlett, J., Cameron, D. A., Campbell, Amy, Dunn, Janet A., Earl, H., Hall, P., Harmer, V., Hughes-Davies, L., Macpherson, I., Makris, A., Morgan, A., Pinder, S. E., Poole, Christopher J., Rea, D., Rooshenas, L., 2020. Strategies to improve recruitment to a de-escalation trial : a mixed-methods study of the OPTIMA prelim trial in early breast cancer. Clinical Oncology
  • Fernando, Indrajit N., Bowden, Sarah J., Herring, Kathryn, Brookes, Cassandra L., Ahmed, Ikhlaaq, Marshall, Andrea, Grieve, Robert J., Churn, Mark, Spooner, David, Latief, Talaat N., Agrawal, Rajiv K., Brunt, Adrian M., Stevens, Andrea, Goodman, Andrew, Canney, Peter, Bishop, Jill, Ritchie, Diana, Dunn, Janet A., Poole, Christopher J., Rea, Daniel W., 2020. Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB) : a randomised, phase III, trial. Radiotherapy and Oncology, 142, pp. 52-61
  • Jepson, Marcus, Elliott, Daisy, Conefrey, Carmel, Wade, Julia, Rooshenas, Leila, Wilson, Caroline, Beard, David, Blazeby, Jane M., Birtle, Alison, Halliday, Alison, Stein, Rob, Donovan, Jenny L., Beard, David, Carr, Andrew, Cook, Jonathan, Cooper, Cushla, Dean, Benjamin, Donovan, Jenny L., Gray, Alastair, Gwilym, Stephen et al (Select to open full list), 2018.

    All authors for An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment

    Jepson, Marcus, Elliott, Daisy, Conefrey, Carmel, Wade, Julia, Rooshenas, Leila, Wilson, Caroline, Beard, David, Blazeby, Jane M., Birtle, Alison, Halliday, Alison, Stein, Rob, Donovan, Jenny L., Beard, David, Carr, Andrew, Cook, Jonathan, Cooper, Cushla, Dean, Benjamin, Donovan, Jenny L., Gray, Alastair, Gwilym, Stephen, Judge, Andrew, Merritt, Naomi, Moser, Jane, Rees, Jonathan, Rombach, Ines, Savulescu, Julian, Tracey, Irene, Wartolowska, Karolina, Blazeby, Jane M., Barham, Paul, Brookes, Sara T., Crosby, Tom, Donovan, Jenny L., Falk, Stephen J., Griffin, S. Michael, Hollingworth, William, Hollowood, Andrew D., Krysztopik, Richard, Lewis, Wyn, Nicklin, Jo, Streets, Christopher, Strong, Sean, Titcomb, Dan, Williams, Geraint, Birtle, Alison, Bryan, Rik, Catto, James, Chester, John, Donovan, Jenny L., French, Ann, Hall, Emma, Harris, Chris, Johnson, Mark, Jones, Rob, Keeley, Francis, Kirkbank, Tony, Kockelbergh, Roger, Lewis, Rebecca, Newton, Michelle, Powles, Thomas, Waters, Rachel, Winterbottom, Andrew, Halliday, Alison, Becquemin, Jean-Pierre, Belli, Anna, Bosiers, Marc, Cao, Piergiorgio, Davies, Christina, Donovan, Jenny L., Gray, Alastair, Gough, Michael, Hayter, Elizabeth, Leopold, Peter, McDonald, Sumaira, Michaels, Jonathan, Mihaylova, Borislava, Peto, Richard, Robertson, Steven, Rothwell, Peter, Scott, Rachael, Thomas, Dafydd, Vermassen, Frank, Stein, Rob, Bartlett, John, Cameron, David, Campbell, Amy, Canney, Peter, Donovan, Jenny L., Dunn, Janet, Earl, Helena, Falzon, Mary, Francis, Adele, Hall, Peter, Harmer, Victoria, Higgins, Helen, Hiller, Louise, Hughes-Davies, Luke, Hulme, Claire, Macpherson, Iain, Makris, Andreas, Marshall, Andrea, McCabe, Christopher, Morgan, Adrienne, Pinder, Sarah, Poole, Christopher J., Rea, Daniel, Stallard, Nigel

    An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. Journal of Clinical Epidemiology, 99, pp. 75-83
  • Guo, Qi, Burgess, Stephen, Turman, Constance, Bolla, Manjeet K., Wang, Qin, Lush, Michael, Abraham, Jean, Aittomäki, Kristiina, Andrulis, Irene L, Apicella, Carmel, Arndt, Volker, Barrdahl, Myrto, Benitez, Javier, Berg, Christine D., Blomqvist, Carl, Bojesen, Stig E, Bonanni, Bernardo, Brand, Judith S, Brenner, Hermann, Broeks, Annegien et al (Select to open full list), 2017.

    All authors for Body mass index and breast cancer survival : a Mendelian randomization analysis

    Guo, Qi, Burgess, Stephen, Turman, Constance, Bolla, Manjeet K., Wang, Qin, Lush, Michael, Abraham, Jean, Aittomäki, Kristiina, Andrulis, Irene L, Apicella, Carmel, Arndt, Volker, Barrdahl, Myrto, Benitez, Javier, Berg, Christine D., Blomqvist, Carl, Bojesen, Stig E, Bonanni, Bernardo, Brand, Judith S, Brenner, Hermann, Broeks, Annegien, Burwinkel, Barbara, Caldas, Carlos, Campa, Daniele, Canzian, Federico, Chang-Claude, Jenny, Chanock, Stephen J., Chin, Suet-Feung, Couch, Fergus J., Cox, Angela, Cross, Simon S., Cybulski, Cezary, Czene, Kamila, Darabi, Hatef, Devilee, Peter, Diver, W Ryan, Dunning, Alison M., Earl, Helena M., Eccles, Diana M., Ekici, Arif B., Eriksson, Mikael, Evans, D Gareth, Fasching, Peter A., Figueroa, Jonine, Flesch-Janys, Dieter, Flyger, Henrik, Gapstur, Susan M., Gaudet, Mia M., Giles, Graham G., Glendon, Gord, Grip, Mervi, Gronwald, Jacek, Haeberle, Lothar, Haiman, Christopher A., Hall, Per, Hamann, Ute, Hankinson, Susan, Hartikainen, Jaana M., Hein, Alexander, Hiller, Louise, Hogervorst, Frans B., Holleczek, Bernd, Hooning, Maartje J., Hoover, Robert N., Humphreys, Keith, Hunter, David J., Hüsing, Anika, Jakubowska, Anna, Jukkola-Vuorinen, Arja, Kaaks, Rudolf, Kabisch, Maria, Kataja, Vesa, Knight, Julia A., Koppert, Linetta B., Kosma, Veli-Matti, Kristensen, Vessela N., Lambrechts, Diether, Le Marchand, Loic, Li, Jingmei, Lindblom, Annika, Lindström, Sara, Lissowska, Jolanta, Lubinski, Jan, Machiela, Mitchell J., Mannermaa, Arto, Manoukian, Siranoush, Margolin, Sara, Marme, Federik, Martens, John WM, McLean, Catriona, Menéndez, Primitiva, Milne, Roger L, Marie Mulligan, Anna, Muranen, Taru A., Nevanlinna, Heli, Neven, Patrick, Nielsen, Sune F., Nordestgaard, Børge G., Olson, Janet E., Perez, Jose I. A., Peterlongo, Paolo, Phillips, Kelly-Anne, Poole, Christopher J., Pylkäs, Katri, Radice, Paolo, Rahman, Nazneen, Rüdiger, Thomas, Rudolph, Anja, Sawyer, Elinor J., Schumacher, Fredrick, Seibold, Petra, Seynaeve, Caroline, Shah, Mitul, Smeets, Ann, Southey, Melissa C., Tollenaar, Rob A. E. M., Tomlinson, Ian, Tsimiklis, Helen, Ulmer, Hans-Ulrich, Vachon, Celine, Ouweland, Ans M. W. van den, Van't Veer, Laura J., Wildiers, Hans, Willett, Walter, Winqvist, Robert, Zamora, M Pilar, Chenevix-Trench, Georgia, Dörk, Thilo, Easton, Douglas F., García-Closas, Montserrat, Kraft, Peter, Hopper, John L., Zheng, Wei, Schmidt, Marjanka K., Pharoah, Paul D. P.

    Body mass index and breast cancer survival : a Mendelian randomization analysis. International Journal of Epidemiology, 46 (6), pp. 1814-1822
  • Dorling, L, Kar, Siddhartha, Michailidou, Kyriaki, Hiller, Louise, Vallier, Anne-Laure, Ingle, Susan, Hardy, Richard, Bowden, Sarah J., Dunn, Janet A., Twelves, Chris, Poole, Christopher J., Caldas, Carlos, Earl, Helena M., Pharoah, Paul D. P., Abraham, Jean E., 2016. The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity : a case-control study. PLoS One, 11 (7)
  • Bartlett, J. M. S., McConkey, Christopher C., Munro, A. F., Desmedt, C., Dunn, Janet A., Larsimont, D., O'Malley, F. P., Cameron, D. A., Earl, H., Poole, Christopher J., Shepherd, L. E., Cardoso, F., Jensen, M., Caldas, C., Twelves, C. J., Rea, D. W., Ejlertsen, B., Di Leo, A., Pritchard, K. I., 2015. Predicting anthracycline benefit : TOP2A and CEP17-not only but also. European Journal of Cancer Care, 33 (15), pp. 1680-1687
  • Bartlett, J., Canney, P., Campbell, A. M., Cameron, D., Donovan, Jenny, Dunn, Janet A., Earl, Helena M., Francis, A., Hall, P., Harmer, V., Higgins, Helen B., Hillier, L., Hulme, C., Hughes-Davies, Luke, Makris, A., Morgan, A., McCabe, Chris, Pinder, S., Poole, Christopher J., Rea, D. et al (Select to open full list), 2013.

    All authors for Selecting breast cancer patients for chemotherapy : the opening of the UK OPTIMA trial

    Bartlett, J., Canney, P., Campbell, A. M., Cameron, D., Donovan, Jenny, Dunn, Janet A., Earl, Helena M., Francis, A., Hall, P., Harmer, V., Higgins, Helen B., Hillier, L., Hulme, C., Hughes-Davies, Luke, Makris, A., Morgan, A., McCabe, Chris, Pinder, S., Poole, Christopher J., Rea, D., Stallard, Nigel, Stein, R.

    Selecting breast cancer patients for chemotherapy : the opening of the UK OPTIMA trial. Clinical Oncology, 25 (2), pp. 109-116
  • Ali, Alaa M., Provenzano, E., Barlett, J. M., Abraham, J., Driver, Kristy, Twelves, Chris, Munro, Alison F., Poole, Christopher, Hiller, Louise, Dunn, Janet A., Earl, Helena M., Caldas, Carlos, Pharoah, Paul, 2013. Prognosis of early breast cancer by immunohistochemistry defined intrinsic subtypes in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. International Journal of Cancer, 133 (6), pp. 1470-1478
  • Ali, Alaa M., Provenzano, Elena, Bartlett, John M. S., Abraham, Jean, Driver, Kristy, Munro, Alison F., Twelves, Chris, Poole, Christopher J., Hiller, Louise, Dunn, Janet A., Earl, Helena M., Caldas, Carlos, Pharoah, Paul D., 2013. Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. International Journal of Cancer, 133 (6), pp. 1470-1478
  • Earl, Helena M., Hiller, Louise, Dunn, Janet A., Vallier, A. -L., Bowden, S. J., Jordan, S. D., Blows, F., Munro, A., Bathers, S., Grieve, R., Spooner, David A., Agrawal, R., Fernando, I., Brunt, A. M., O'Reilly, S. M., Crawford, S. Michael, Rea, D. W., Simmonds, P., Mansi, J. L., Stanley, A. et al (Select to open full list), 2012.

    All authors for Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer : results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials

    Earl, Helena M., Hiller, Louise, Dunn, Janet A., Vallier, A. -L., Bowden, S. J., Jordan, S. D., Blows, F., Munro, A., Bathers, S., Grieve, R., Spooner, David A., Agrawal, R., Fernando, I., Brunt, A. M., O'Reilly, S. M., Crawford, S. Michael, Rea, D. W., Simmonds, P., Mansi, J. L., Stanley, A., McAdam, K., Foster, Liz, Leonard, R. C. F., Twelves, Chris, Cameron, D., Bartlett, J. M. S., Pharoah, P., Provenzano, E., Caldas, C., Poole, Christopher J.

    Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer : results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. British Journal of Cancer, Vol.107 (No.8), pp. 1257-1267
  • Campbell, H. E., Epstein, D., Bloomfield, D., Griffin, S., Manca, A., Yarnold, J., Bliss, J., Johnson, L., Earl, Helena M., Poole, Christopher J., Hiller, Louise, Dunn, Janet A., Hopwood, P., Barrett-Lee, P., Ellis, P., Cameron, D., Harris, A. L., Gray, A. M., Sculpher, Mark J., 2011. The cost-effectiveness of adjuvant chemotherapy for early breast cancer : a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. European Journal of Cancer, Vol.47 (No.17), pp. 2517-2530
  • Leo, Angelo Di, Desmedt, Christine, Bartlett, John M. S., Piette, Fanny, Ejlertsen, Bent, Pritchard, Kathleen I., Larsimont, Denis, Poole, Christopher J., Isola, Jorma, Earl, Helena M., Mouridsen, H. T., O'Malley, Frances P., Cardoso, Fatima, Tanner, Minna, Munro, A., Twelves, Chris, Sotiriou, Christos, Shepherd, Lois, Cameron, D., Piccart, Martine J. et al (Select to open full list), 2011.

    All authors for HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer : a meta-analysis of individual patient data

    Leo, Angelo Di, Desmedt, Christine, Bartlett, John M. S., Piette, Fanny, Ejlertsen, Bent, Pritchard, Kathleen I., Larsimont, Denis, Poole, Christopher J., Isola, Jorma, Earl, Helena M., Mouridsen, H. T., O'Malley, Frances P., Cardoso, Fatima, Tanner, Minna, Munro, A., Twelves, Chris, Sotiriou, Christos, Shepherd, Lois, Cameron, D., Piccart, Martine J., Buyse, Marc E.

    HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer : a meta-analysis of individual patient data. Lancet Oncology, Vol.12 (No.12), pp. 1134-1142
  • Rustin, G., Reed, N., Jayson, G. C., Ledermann, J. A., Adams, M., Perren, T., Poole, Christopher, Lind, M., Persic, M., Essapen, S., Gore, M., Calvert, H., Stredder, C., Wagner, A., Giurescu, M., Kaye, S., 2011. A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Annals of Oncology, Vol.22 (No.11), pp. 2411-2416
  • Forster, Martin D., Dedes, Konstantin J., Sandhu, Shahneen, Frentzas, Sophia, Kristeleit, Rebecca, Ashworth, Alan, Poole, Christopher J., Weigelt, Britta, Kaye, Stan B., Molife, L. Rhoda, 2011. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nature Reviews. Clinical Oncology, 8 (5), pp. 302-306
  • Bartlett, John M. S., Munro, Alison F., Dunn, Janet A., McConkey, Christopher C., Jordan, S., Twelves, Chris, Cameron, D., Thomas, Jeremy St. J., Campbell, Fiona M., Rea, Daniel W., Provenzano, Elena, Caldas, Carlos, Pharaoh, Paul, Hiller, Louise, Earl, Helena M., Poole, Christopher, 2010. Predictive markers of anthracycline benefit : a prospectively planned analysis of the UK national epirubicin adjuvant trial (NEAT/BR9601). Lancet Oncology, Vol.11 (No.3), pp. 266-274
  • Ellis, Paul, Barrett-Lee, Peter, Johnson, Lindsay, Cameron, David, Wardley, Andrew, O'Reilly, Susan, Verrill, Mark, Smith, Ian, Yarnold, John, Coleman, Robert, Earl, Helena M., Canney, Peter, Twelves, Chris, Poole, Christopher J., Bloomfield, David, Hopwood, Penelope, Johnston, Stephen, Dowsett, Mitchell, Bartlett, John M. S., Ellis, Ian et al (Select to open full list), 2009.

    All authors for Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT) : an open-label, phase III, randomised controlled trial

    Ellis, Paul, Barrett-Lee, Peter, Johnson, Lindsay, Cameron, David, Wardley, Andrew, O'Reilly, Susan, Verrill, Mark, Smith, Ian, Yarnold, John, Coleman, Robert, Earl, Helena M., Canney, Peter, Twelves, Chris, Poole, Christopher J., Bloomfield, David, Hopwood, Penelope, Johnston, Stephen, Dowsett, Mitchell, Bartlett, John M. S., Ellis, Ian, Peckitt, Clare, Hall, Emma, Bliss, Judith M.

    Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT) : an open-label, phase III, randomised controlled trial. Lancet, Vol.373 (No.9676), pp. 1681-1692
  • Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, S., Harvey, P., Stanley, A., Grieve, R. J., Agrawal, R. K., Fernando, I. N., Brunt, A. M., McAdam, K., O'Reilly, S., Rea, D. W., Spooner, David A., Poole, Christopher, 2008. NEAT : national epirubicin adjuvant trial - toxicity, delivered dose intensity and quality of life. British Journal of Cancer, Vol.99 (No.8), pp. 1226-1231
  • Wardley, A. M., Hiller, Louise, Howard, H. C., Dunn, Janet A., Bowman, A., Coleman, R. E., Fernando, I. N., Ritchie, D. M., Earl, Helena M., Poole, Christopher J., 2008. tAnGo : a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer : a prospective pulmonary, cardiac and hepatic function evaluation. British Journal of Cancer, Vol.99 (No.4), pp. 597-603
  • Kaye, Stan B., Poole, Christopher, Bidzinksi, M., Gianni, L., Gorbunova, V., Novikova, E., Strauss, A., McNally, V. A., Rossi, G., Vergote, Ignace, 2008. A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology, Vol.26 (No.15S)
  • Poole, Christopher J., Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, Sarah, Grieve, Robert J., Spooner, David A., Agrawal, Rajiv K., Brunt, A. Murray, O'Reilly, Susan M., Crawford, S. Michael, Rea, Daniel W., Simmonds, Peter, Mansi, Janine L., Stanley, Andrew, Harvey, Peter, McAdam, Karen, Foster, Liz, Leonard, Robert C. F., Twelves, Chris, 2006. Epirubicin and cyclophosphamide, methotrexate,and fluorouracil as adjuvant therapy for early breast cancer. New England Journal of Medicine, Vol.355 (No.18), pp. 1851-1862
Title Funder Award start Award end
BAYER - Investigator led research proposal: *SELECT-D* Duration of anticoagulation therapy in SELECTeD patients with advanced cancer at risk of recurrence of venous thromboembolism - Bayer plc 01 Oct 2012 30 Sep 2015
NEOESCAPE - Neoadjuvant extended sequential chemotherapy with adjuvant post-operative treatment with epithelial ovarian cancer Cancer Research UK 01 Oct 2008 30 Sep 2009